[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"diabetes-type1\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:diabetes-type1":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,53,79],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":32,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":41,"lastUpdatePostDateStruct":42,"startDateStruct":45,"completionDateStruct":47,"leadSponsor":49,"locationsCount":52},"100547238","behavioral-approaches-to-reduce-diabetes-distress-in-adults-with-type-1-diabetes-a-pragmatic-smart-100547238",false,"NCT06405373","Behavioral Approaches to Reduce Diabetes Distress in Adults With Type 1 Diabetes: A Pragmatic SMART","Fusing Rapid-cycle Testing and Adaptive Trial Designs: A Scientific Pipeline to Translate and Individualize Evidence-based Psychosocial and Behavioral Interventions in Routine Type 1 Diabetes Care","ChargeUp","Inclusion Criteria:\n\n* Adults 30 years and older\n* Type 1 diabetes OR latent autoimmune diabetes in adults (LADA) clinically managed as type 1 diabetes\n* Elevated diabetes distress, defined as a score \\>= 2.0 on the T1-DDAS core scale\n* English speaking\n\nExclusion Criteria:\n\n* Does not receive diabetes care at UNC Endocrinology at Eastowne\n* Cannot commit to the pre-scheduled weekly, virtual sessions\n* Diagnosis of any major medical or psychiatric condition that would preclude participation\n* Diagnosis of dementia or other conditions that affect memory or information retention, such as cognitive impairment\n* Visual or auditory impairment that would interfere with participation in a group intervention\n* Receiving inpatient psychiatric treatment or history of a suicide attempt within the past 12 months at the time of enrollment","ALL","30 Years",{"count":20,"type":21},200,"ESTIMATED","INTERVENTIONAL",[24],"NA","This study is designed to compare two behavioral approaches to reduce diabetes distress (\"the expected burdens, concerns, fears, and threats that arise from the challenges of living with diabetes\") in adults with type 1 diabetes. At the study baseline, participants will be randomized to take part in one of two virtual, group-based interventions (the \"Primary\" intervention) utilizing either an emotions-focused or a problem-solving approach to reduce diabetes distress. After the initial intervention, participants will complete surveys to assess their response to the material. Participants who are determined to be \"non-responders\" (i.e., the Primary intervention was not effective) will be re-randomized to one of two \"Supplementary\" interventions, which will include individualized sessions to learn and\u002For practice strategies related to either the psychological or problem-solving approach.",[27,28,29,30,31],"Diabetes type1","Diabetes Mellitus, Type 1","Diabetes, Autoimmune","Diabetes Mellitus","Distress, Emotional",[33,34,35,36,37,38,39],"Diabetes","Type 1 diabetes","Diabetes distress","T1D","Emotional distress","Telehealth","SMART design","RECRUITING","2025-10-28",{"date":43,"type":44},"2025-10-29","ACTUAL",{"date":46,"type":44},"2024-10-01",{"date":48,"type":21},"2027-09-15",{"name":50,"class":51},"University of North Carolina, Chapel Hill","OTHER",1,{"id":54,"slug":55,"hasResults":11,"nctId":56,"briefTitle":57,"officialTitle":58,"acronym":59,"eligibilityCriteria":60,"healthyVolunteers":11,"sex":17,"minAge":61,"maxAge":4,"enrollmentInfo":62,"targetDuration":4,"studyType":64,"phases":4,"briefSummary":65,"conditions":66,"keywords":4,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":78},"100549726","exploration-of-health-literacy-in-diabetes-in-reunion-island-and-france-100549726","NCT06437782","Exploration of Health Literacy in Diabetes in Reunion Island and France","Exploration of Health Literacy in Diabetes in Reunion Island and Metropolitan France","HLQ-Diabete","Inclusion Criteria:\n\nPatient with type 1, 2 or gestational diabetes taken care in hospital\n\nExclusion Criteria:\n\n* Patient unable to understand and respect study procedures\n* Patient with cognitive disorder\n* Patient with serious acute complication due to diabetes within 15 days before inclusion\n* Stroke history with neurologic consequences\n* Other specific types of diabetes : chronic calcific pancreatitis, iatrogenic, other secondary diabetes, rare monogenic or genetic diabetes due to insulin resistance","18 Years",{"count":63,"type":21},1350,"OBSERVATIONAL","The goal of this observational study is to identify the health literacy profile of diabetic patients in Reunion Island and France in order to obtain information to improve access to information, therapeutic education and to health service. The main question\\[s\\] it aims to answer \\[is\u002Fare\\]:\n\nParticipants will complete the Health Literacy Questionnaire (HLQ) once.",[27,67,68],"Diabetes Type 2","Diabetes, Gestational","2025-07-28",{"date":71,"type":44},"2025-07-30",{"date":73,"type":44},"2025-04-17",{"date":75,"type":21},"2026-06",{"name":77,"class":51},"Centre Hospitalier Universitaire de la Réunion",2,{"id":80,"slug":81,"hasResults":11,"nctId":82,"briefTitle":83,"officialTitle":84,"acronym":4,"eligibilityCriteria":85,"healthyVolunteers":11,"sex":17,"minAge":61,"maxAge":18,"enrollmentInfo":86,"targetDuration":4,"studyType":22,"phases":88,"briefSummary":90,"conditions":91,"keywords":4,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":52},"100547687","phase-2-obesity-complicating-type-1-diabetes-glp-1-analogue-anti-obesity-treatment-100547687","NCT06411210","Obesity Complicating Type 1 Diabetes: GLP-1 Analogue Anti-obesity Treatment","Obesity Complicating Type 1 Diabetes in Young Adults: Physiology and Impact of GLP-1 Analogue Anti-obesity Treatment on Cardiometabolic Risk Factors","Inclusion Criteria:\n\n* Age 18-30 years with T1D whose BMI meets FDA approval criteria for anti-obesity pharmacotherapy (BMI ≥30 kg\u002Fm2 alone or BMI ≥27 kg\u002Fm2 with a weight-related comorbidity)\n* Clinical diagnosis of T1D\n* Diabetes duration diagnosed ≥ 12 months ago\n* HbA1c ≤10% at screening and within the past 90 days\n* Stable reported insulin dosing in the past 90 days (within 15%)\n* Stable reported BMI in the past 90 days (within 5%)\n* Ability to provide written informed consent before any trial-related activities\n* Use of real-time continuous glucose monitoring and planned continued use\n* Females and males of childbearing potential willing to use highly effective methods of contraception for at least 1 month prior to randomization and agreement to use such a method during study participation and for 2 months after the last dose of study medication administration: Combined estrogen-progestogen contraception including: oral, intravaginal, transdermal (patch), Progestogen-only contraception: oral, injectable or implantable, Placement of an intrauterine device or intrauterine system, Bilateral tubal occlusion (fallopian tubes are blocked), Male partner sterilization (with the appropriate post-vasectomy documentation of the absence of sperm in the ejaculate), or Complete sexual abstinence from male-female sex)\n* Stated willingness to comply with all study procedures, medication regimen, and availability for the duration of the study\n* Participants cannot be randomized if any laboratory safety parameter at screening is outside the below extended laboratory ranges. For randomization, participants should have\n\n  1. Creatinine \\\u003C1.0mg\n  2. Triglycerides (\\\u003C400 mg\u002Fdl)\n  3. ALT \\\u003C3.5 times the upper normal limit (UNL)\n\nExclusion Criteria:\n\n* Use of adjunctive diabetes therapies or anti-obesity medications (including any GLP-1 agonist) currently or within the past 6 months.\n* Insulin dosing \\\u003C0.5 units\u002Fkg\u002Fday\n* Current psychiatric conditions impacting weight, including known eating disorders\n* Contraindications to study medications, including:\n\n  * Personal history of pancreatitis, renal impairment, or known liver disease other than non-alcoholic hepatic steatosis\n  * Personal or family history of medullary thyroid cancer or Multiple Endocrine Neoplasia Type 2\n  * Known or suspected allergy to semaglutide, excipients, or related products.\n* Use of lipid lowering medications other than statins and omega-3 products\n* Previous randomization in this trial. Participants who enrolled but did not randomize can be re-screened. Potential reasons for enrolment without randomization include scheduling conflicts for the baseline studies, or for females, not yet meeting the highly effective methods of contraception criteria.\n* Pregnant, breast-feeding or the intention of becoming pregnant or not using adequate contraceptive measures\n* Diabetic ketoacidosis in the past 6 months\n* Not meeting MRI safety criteria or claustrophobia preventing participation in the MRI\n* Anemia or known hematologic condition impacting HbA1c reading, or another medical condition that precludes participation.\n* Treatment with another investigational drug or other intervention within the past 1 month\n* Subjects with a PHQ-9 score \\>15 or those found to have a lifetime history of suicide attempts, or suicidal ideation within the past 3 months on the C-SSRS\n* Corn allergy\n* Subjects with severe hypoglycemia requiring hospitalization in the past 3 months\n* Clinically significant gastroparesis",{"count":87,"type":21},54,[89],"PHASE2","More than 40% of young adults with type 1 diabetes (T1D) also have overweight or obesity. Each of these diagnoses increase the risk of adverse cardiovascular events. GLP-1 analogues are anti-obesity medications that are cardioprotective in adults with type 2 diabetes, however evaluation of these agents in people with T1D has been limited to glycemic outcomes. Investigators aim to study the impact of GLP-1 analogue obesity treatment on markers of cardiometabolic risk in young adults with T1D and obesity.",[27,92],"Obesity","2025-04-29",{"date":95,"type":44},"2025-05-02",{"date":97,"type":44},"2024-07-16",{"date":99,"type":21},"2028-06-30",{"name":101,"class":51},"Yale University"]